clinical trial · NCT07365904
Investigating Ovulation Inhibition for Use as a Contraceptive
ContraceptionMR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
brief summary
A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch
started
Dec 22, 2025
primary completion
Nov 30, 2026
completion
Nov 30, 2026
last updated
Jan 26, 2026
detailed description
Ovulation inhibition study of MR-130A-01 contraceptive transdermal patch containing norelgestromin with intentional application errors; MR-130A-01-TD-2002
official title
A Single-centre, Open-label, Phase II Study on the Maintenance of Ovulation Inhibition After Intentional Application Contraceptive
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol